$AMZN

Amazon.com, Inc. (AMZN) vs. Apple Inc. (AAPL): Hedge Funds Favor One over the Other

Insider Monkey reports that Amazon (AMZN) and Apple (AAPL) both beat revenue estimates, but shares moved in opposite directions. Amazon’s AWS revenue rose 37% to $42.2B and revenue was $200.61B; stock jumped up to 15%. Apple revenue was $109.42B, iPhone sales rose 22% to $54.25B, but guidance citing supply constraints and EPS of $1.91 led shares to fall over 7%.

Original reporting
Published Aug 11, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Amazon.com, Inc. (AMZN) vs. Apple Inc. (AAPL): Hedge Funds Favor One over the Other — source image
Decision brief

The 30-second read

$AMZNBullishMed
01

Why it matters

The trading focus is the combination of (1) AWS growth and raised capex for AMZN versus (2) Apple’s guidance shortfall tied to memory constraints, despite revenue and iPhone strength.

02

Market read

This is a same-day earnings reaction story emphasizing AWS acceleration and capex/FCF tradeoffs for AMZN, versus Apple’s guidance miss despite product beats.

03

What to watch

For AMZN, the pretax gain tied to Anthropic stake and the backlog/demand framing may not translate immediately into FCF. For AAPL, the guidance miss could be temporary if memory supply normalizes, making the selloff potentially overshoot.

Relevance 7/10Novelty 4/10Timing: after-hours/next-session positioning following the same earnings day reaction

Background

Both Amazon and Apple reported earnings in the same week, with the article contrasting AWS/AI momentum versus Apple’s hardware guidance and supply-constraint explanations.

Company-level read

Ticker impact

$AMZNBullishMedium confidence
Context

Amazon’s AWS revenue grew 37% YoY and management raised 2026 capex to $220B, while free cash flow turned negative.

Expected impact

Likely supports a rebound bias if investors focus on AWS growth and booked demand, but keeps volatility elevated due to negative trailing FCF and softer revenue guidance.

Evidence & confidence

The article cites AWS acceleration, backlog/demand commentary, and a capex increase, alongside a $7.6B FCF deterioration and guidance below consensus, which can drive two-sided positioning.

$AAPLBearishMedium confidence
Context

Apple beat revenue and iPhone sales but guided current-quarter growth below expectations, citing supply constraints from a global memory shortage.

Expected impact

Near-term downside risk persists while memory constraints and weaker guidance remain the dominant narrative, even if product momentum is strong.

Evidence & confidence

The article highlights revenue and iPhone/Mac outperformance but emphasizes guidance miss and supply-constraint explanations, which typically matter most for near-term trading.

Market effects

Reinforces a split narrative for mega-cap tech: cloud/AI spend getting rewarded versus consumer hardware constrained by memory supply and guidance.

Mentions Apple’s China sales growth, but the main driver is global memory constraints rather than a region-specific shock.

Memory shortage is treated as a global input constraint, linking Apple’s near-term outlook to broader semiconductor supply conditions.

Counterpoint

The article may over-attribute AMZN’s move to AI payback and AAPL’s drop to memory constraints; the real driver could be relative guidance versus expectations and one-off items.

Key entities

  • Amazon.com, Inc.

    AWS grew 37% YoY; capex plan raised to $220B; trailing FCF turned negative; guidance below consensus.

  • Apple Inc.

    Revenue and iPhone sales beat; guidance for current quarter missed; cited global memory shortage; CEO Tim Cook’s last quarter as chief executive.

  • Anthropic

    Amazon’s stake generated a $53.4B pretax gain mentioned in the article.

Related articles

$AAPLMed

Apple Stock Falls Again After Jefferies Slashes Rating

Apple shares fell about 0.5% Tuesday after Jefferies downgraded AAPL to Underperform from Hold and cut its price target to about $264 from $286. Jefferies cited concerns about AI execution and higher memory costs, plus supply-chain signals around a rumored iPhone redesign. Apple reported June-quarter revenue of $109.4B (+16%) and EPS of $2.02 (+29%).

$AMZNMed

Amazon AI Center Could Become the Largest Polluter in the US

Amazon Web Services plans a large data center in Pecos County, Texas, backed by a gas-fired power plant. The New York Times says Amazon confirmed investment in a plant expected to supply up to 7.65 GW. The 35 turbines could emit up to 33 million tons of CO2 annually, potentially making it the largest US source. Amazon cites changing circumstances and reported rising emissions and 34% higher electricity use in 2025.

$NVDAMed

NVIDIA CEO Jensen Huang Just Announced $500 Billion in New Funding: Here’s Why Amazon, Microsoft, and Google Are Taking It Hard.

NVIDIA CEO Jensen Huang announced a financing framework with Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR to mobilize over $500B of third-party capital for AI data center “factory” buildouts, positioning GPU compute as revenue-generating infrastructure. NVIDIA shares edged higher. Cloud peers including Amazon, Microsoft and Alphabet traded lower, while CoreWeave rose.

$AAPLMed

Apple Q3 2026: Record Revenue, Tariff Refund, and Supply Warnings

Apple reported Q3 FY2026 revenue of $109.4 billion, up 16% year over year, and said it had 1.5 billion paid subscriptions. The company also reported a $2.19 billion tariff refund and record $11.73 billion R&D spending. On its earnings call, Apple warned supply constraints will worsen “significantly” next quarter.

$CVSMed

1 Bridge reshapes drug pricing

CMS’s Medicare GLP-1 Bridge program will let eligible Medicare Part D beneficiaries access certain GLP-1 weight-management drugs for a $50 monthly copay from July 1, 2026 through Dec. 31, 2027, outside the usual Part D deductible and TrOOP rules, with CMS using a central processor. CVS, Walgreens, Publix, Amazon Pharmacy, Novo Nordisk, and Eli Lilly are participating.